253 related articles for article (PubMed ID: 32376735)
1. β-catenin and PD-L1 expression in mismatch repair deficient endometrial carcinomas.
Rowe M; Krishnan R; Mills A; Ring K
Int J Gynecol Cancer; 2020 Jul; 30(7):993-999. PubMed ID: 32376735
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
3. Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas.
Mills A; Zadeh S; Sloan E; Chinn Z; Modesitt SC; Ring KL
Mod Pathol; 2018 Aug; 31(8):1282-1290. PubMed ID: 29559741
[TBL] [Abstract][Full Text] [Related]
4. Diffuse Intratumoral Stromal Inflammation in Ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression.
Lin SY; Hang JF; Lin YY; Lai CR; Ho HL; Chou TY
Int J Gynecol Pathol; 2021 Mar; 40(2):148-155. PubMed ID: 32897958
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinoma and Tumor-associated Immune Cells: Differences Between MLH1 Methylated and Nonmethylated Subgroups.
Kir G; Olgun ZC; Soylemez T; Aydin A; Demircan B; Kaya IA; McCluggage WG
Int J Gynecol Pathol; 2021 Nov; 40(6):575-586. PubMed ID: 33332859
[TBL] [Abstract][Full Text] [Related]
6. Programmed Death Ligand 1 Expression Among 700 Consecutive Endometrial Cancers: Strong Association With Mismatch Repair Protein Deficiency.
Li Z; Joehlin-Price AS; Rhoades J; Ayoola-Adeola M; Miller K; Parwani AV; Backes FJ; Felix AS; Suarez AA
Int J Gynecol Cancer; 2018 Jan; 28(1):59-68. PubMed ID: 29053481
[TBL] [Abstract][Full Text] [Related]
7. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.
Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ
Front Immunol; 2019; 10():3023. PubMed ID: 31998307
[TBL] [Abstract][Full Text] [Related]
8. TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers.
Moore M; Ring KL; Mills AM
Mod Pathol; 2019 Jul; 32(8):1168-1179. PubMed ID: 30926882
[TBL] [Abstract][Full Text] [Related]
9. Tumor site discordance in mismatch repair deficiency in synchronous endometrial and ovarian cancers.
Kim SR; Tone A; Kim R; Cesari M; Clarke B; Eiriksson L; Hart T; Aronson M; Holter S; Lytwyn A; Maganti M; Oldfield L; Gallinger S; Bernardini MQ; Oza AM; Djordjevic B; Lerner-Ellis J; Van de Laar E; Vicus D; Pugh TJ; Pollett A; Ferguson SE
Int J Gynecol Cancer; 2020 Dec; 30(12):1951-1958. PubMed ID: 33082239
[TBL] [Abstract][Full Text] [Related]
10. MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.
Hacking S; Jin C; Komforti M; Liang S; Nasim M
Pathol Res Pract; 2019 Oct; 215(10):152552. PubMed ID: 31353229
[TBL] [Abstract][Full Text] [Related]
11. Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?
Kahn RM; Gordhandas S; Maddy BP; Baltich Nelson B; Askin G; Christos PJ; Caputo TA; Chapman-Davis E; Holcomb K; Frey MK
Cancer; 2019 Sep; 125(18):3172-3183. PubMed ID: 31150123
[TBL] [Abstract][Full Text] [Related]
12. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
Bregar A; Deshpande A; Grange C; Zi T; Stall J; Hirsch H; Reeves J; Sathyanarayanan S; Growdon WB; Rueda BR
Gynecol Oncol; 2017 Jun; 145(3):446-452. PubMed ID: 28347512
[TBL] [Abstract][Full Text] [Related]
13. Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium.
Willis BC; Sloan EA; Atkins KA; Stoler MH; Mills AM
Mod Pathol; 2017 Nov; 30(11):1622-1632. PubMed ID: 28752845
[TBL] [Abstract][Full Text] [Related]
14. The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma.
Mills AM; Dill EA; Moskaluk CA; Dziegielewski J; Bullock TN; Dillon PM
Am J Surg Pathol; 2018 Feb; 42(2):183-191. PubMed ID: 28914717
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and molecular characteristics of DNA mismatch repair deficient endometrial cancer in a Japanese hospital-based population.
Yamamoto A; Yamaguchi T; Suzuki O; Ito T; Chika N; Kamae N; Tamaru JI; Nagai T; Seki H; Arai T; Tachikawa T; Akagi K; Eguchi H; Okazaki Y; Ishida H
Jpn J Clin Oncol; 2021 Jan; 51(1):60-69. PubMed ID: 32844218
[TBL] [Abstract][Full Text] [Related]
16. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
17. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
Timmerman S; Van Rompuy AS; Van Gorp T; Vanden Bempt I; Brems H; Van Nieuwenhuysen E; Han SN; Neven P; Victoor J; Laenen A; Vergote I
Gynecol Oncol; 2020 Apr; 157(1):245-251. PubMed ID: 31980219
[TBL] [Abstract][Full Text] [Related]
18. EPM2AIP1 Immunohistochemistry Can Be Used as Surrogate Testing for MLH1 Promoter Methylation in Endometrial Cancer.
Mrkonjic M; Turashvili G
Am J Surg Pathol; 2022 Mar; 46(3):376-382. PubMed ID: 34772843
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological features of 50 mismatch repair (MMR)-deficient endometrial carcinomas, tested by immunohistochemistry: A single institutional feasibility study, India.
Rekhi B; Menon S; Deodhar KK; Ghosh J; Chopra S; Maheshwari A
Ann Diagn Pathol; 2020 Aug; 47():151558. PubMed ID: 32619922
[TBL] [Abstract][Full Text] [Related]
20. Germline MLH1 Mutations Are Frequently Identified in Lynch Syndrome Patients With Colorectal and Endometrial Carcinoma Demonstrating Isolated Loss of PMS2 Immunohistochemical Expression.
Dudley B; Brand RE; Thull D; Bahary N; Nikiforova MN; Pai RK
Am J Surg Pathol; 2015 Aug; 39(8):1114-20. PubMed ID: 25871621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]